-+ 0.00%
-+ 0.00%
-+ 0.00%
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Share
Listen to the news

HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to leptomeningeal metastases (LM), a serious and often underdiagnosed complication of advanced cancer.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending